Countering Coupons: Large Employers Will Boost Copay Accumulator Programs In 2021

Annual large US employer health benefits survey also evaluates plans for managing the cost of cell and gene therapies in the coming years, anticipating growing use of outcomes-based contracts, but very limited uptake of payment-over-time models.

Businessman hand stops domino continuous overturned meaning that hindered business failure. Stop over this business failure concept.
Payers Increasingly Seeking To Halt Use Of Manufacturer Coupons.

More from Cell & Gene Therapies

More from Advanced Technologies